ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC raised its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 0.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,238,156 shares of the company’s stock after buying an additional 3,351 shares during the quarter. Geode Capital Management LLC owned about 1.27% of ARS Pharmaceuticals worth $13,066,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of SPRY. Alliancebernstein L.P. lifted its holdings in shares of ARS Pharmaceuticals by 5,168.4% in the 4th quarter. Alliancebernstein L.P. now owns 3,880,734 shares of the company’s stock worth $40,942,000 after acquiring an additional 3,807,074 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of ARS Pharmaceuticals in the 4th quarter valued at $6,576,000. Peregrine Capital Management LLC acquired a new position in ARS Pharmaceuticals during the 4th quarter worth about $4,469,000. Royce & Associates LP boosted its holdings in ARS Pharmaceuticals by 34.4% during the 4th quarter. Royce & Associates LP now owns 929,613 shares of the company’s stock valued at $9,807,000 after acquiring an additional 238,158 shares during the period. Finally, Levin Capital Strategies L.P. grew its position in ARS Pharmaceuticals by 56.2% in the 4th quarter. Levin Capital Strategies L.P. now owns 467,627 shares of the company’s stock valued at $4,933,000 after acquiring an additional 168,201 shares in the last quarter. Hedge funds and other institutional investors own 68.16% of the company’s stock.

Insiders Place Their Bets

In other ARS Pharmaceuticals news, Director Laura Shawver sold 49,600 shares of the firm’s stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $11.21, for a total transaction of $556,016.00. Following the transaction, the director now directly owns 210,346 shares of the company’s stock, valued at approximately $2,357,978.66. This trade represents a 19.08 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Eric Karas sold 10,000 shares of the company’s stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $14.00, for a total transaction of $140,000.00. Following the completion of the sale, the insider now directly owns 7,696 shares of the company’s stock, valued at $107,744. The trade was a 56.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 159,602 shares of company stock valued at $1,926,541. 40.10% of the stock is currently owned by insiders.

ARS Pharmaceuticals Stock Performance

SPRY opened at $14.32 on Tuesday. The business’s 50-day simple moving average is $12.32 and its 200-day simple moving average is $13.04. The company has a market cap of $1.41 billion, a P/E ratio of -28.08 and a beta of 0.86. ARS Pharmaceuticals, Inc. has a one year low of $7.55 and a one year high of $18.51.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its quarterly earnings data on Thursday, March 20th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.56. The company had revenue of $86.58 million for the quarter, compared to analyst estimates of $15.46 million. As a group, analysts predict that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on SPRY shares. Raymond James increased their price target on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, January 14th. Oppenheimer initiated coverage on ARS Pharmaceuticals in a research report on Monday, February 10th. They set an “outperform” rating and a $40.00 price objective on the stock. Leerink Partners lifted their target price on ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a report on Monday, January 13th. William Blair reaffirmed an “outperform” rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. Finally, Scotiabank initiated coverage on ARS Pharmaceuticals in a research report on Friday, March 7th. They set a “sector outperform” rating and a $30.00 price objective for the company. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, ARS Pharmaceuticals currently has an average rating of “Buy” and an average price target of $31.00.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.